Clinical Trials Directory

Trials / Completed

CompletedNCT05130073

4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

The Role of a 4-point Therapy Response Score With PET/CT Post Definitive Chemoradiation for Anal Squamous Cell Cancer: A Prospective Study

Status
Completed
Phase
Study type
Observational
Enrollment
41 (actual)
Sponsor
M.D. Anderson Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study determines whether a positron emission tomography (PET)/computed tomography (CT) 4-point scoring system may predict overall survival for anal squamous cell cancer patients. A 4-point scoring system involving imaging scans may help to predict how patients with anal squamous cell cancer respond to chemoradiation therapy.

Detailed description

PRIMARY OBJECTIVE: I. To determine whether a PET/CT scoring system in invasive biopsy proven anal squamous cell carcinoma (SCCA) to be treated with chemoradiation with curative intent (any T any N) predicts for overall survival (OS). SECONDARY OBJECTIVES: I. To determine whether a PET/CT scoring system in invasive biopsy proven SCCA to be treated with definitive chemoradiation with curative intent predicts for progression free survival (PFS). II. To determine and validate inter-reader reliability. III. To calculate C-index to evaluate the prognostic capacity of PET/CT scores for survival. IV. To determine the association between pre-treatment PET/CT scores after treatment and OS. EXPLORATORY OBJECTIVE: I. To correlate level of standardized uptake value (SUV) pre and post therapy and its correlation with overall survival. OUTLINE: Patients undergo PET/CT at baseline and at 3 months post therapy completion. Patients' medical records are received. Patients are followed up for 5 years.

Conditions

Interventions

TypeNameDescription
PROCEDUREComputed TomographyUndergo PET/CT
OTHERElectronic Health Record ReviewReview of medical records
PROCEDUREFollow-UpUndergo follow-up
PROCEDUREPositron Emission TomographyUndergo PET/CT

Timeline

Start date
2019-07-31
Primary completion
2023-12-14
Completion
2023-12-14
First posted
2021-11-22
Last updated
2024-02-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05130073. Inclusion in this directory is not an endorsement.